투자판단관련주요경영사항 (경구용 당뇨 치료제 리벨서스 제네릭 및 경구용 비만 치료제 위고비 오럴 제네릭(세마글루타이드) 미국 라이센스 계약 체결)[코]
Received: 3/30/2026 · Reporter: 삼천당제약
A summary for this filing type is not yet available. Please refer to the original DART filing.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 32 filings
- Same category
- 25 filings
- Previous same-category filing
- 6/10/2026
- Corrections / withdrawals
- 3 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).